drugset
Drugs / NGGT002
last change Jul 2026 re-read 3 minutes ago

NGGT002

Gene therapy (AAV / viral vector)

Developed for
phenylketonuria · classic phenylketonuria
Investigated by
NGGT (Suzhou) Biotechnology Co., Ltd. · NGGT INC. · The First Affiliated Hospital of Bengbu Medical University

Trials 3

today NCT06332807 · Ph 1/2 NCT06687733 · Ph 1/2 NCT06061614 · Ph 0
20242025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06061614 Mar 2023 → Dec 2028 expected phenylketonuria The First Affiliated Hospital of Bengbu Medical University Recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT06332807 Jan 2025 → Dec 2030 expected classic phenylketonuria NGGT INC. Recruiting No outcome recorded
Phase 1/2 NCT06687733 Jul 2024 → Jul 2026 overdue phenylketonuria NGGT (Suzhou) Biotechnology Co., Ltd. Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as NGGT002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06687733 ↗
2

NCT06332807 ↗

NCT06061614 ↗
Action Restore “carrying a functional copy of the human PAH gene” NCT06687733 ↗
Modality Gene therapy (AAV / viral vector) “rAAV8 based vector” NCT06332807 ↗
Route Intravenous “NGGT002 will be administered via intravenous infusion.” NCT06061614 ↗